Drug News
Nursing November 17, 2023 DOI: 10.1097/01.nurse.0000991564.66899.fc (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractLorazepam is associated with worse progression-free survival. A co-treatment approach improves efficacy. The FDA's approval process for certain drugs is questionable. Updates to toxicity diagnosis and management are provided. A method to identify children with acute sinusitis who are likely to benefit from antibiotics is described. Psilocybin is presented as a novel intervention for depression.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Lorazepam Sinusitis Depression economics Intensive care medicine |
| Key finding | Lorazepam is associated with worse progression-free survival. |
Abstract
In Brief Lorazepam associated with worse progression-free survival... Examining long-term medication effects... The co-treatment approach improves efficacy... Article details FDA's questionable approval... Updates to toxicity diagnosis and management... Identifying children with acute sinusitis who are likely to benefit from antibiotics... Psilocybin as a novel Intervention for depression